PACSIN3

Across TCGA pan-cancer cohorts, PACSIN3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PACSIN3 data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher PACSIN3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PACSIN3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

GBM, PDAC, and LUAD are the cancer types where PACSIN3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.261	0.431	.010	7	view →
PDAC	OS	Tertile	IV	0.962	0.472	.024	6	view →
LUAD	OS	Median	III,IV	0.396	0.897	.038	2	view →
LSCC	DFS	Quartile	II,III,IV	0.939	0.657	.048	1	view →
HNSC	DFS	Median	III,IV	1.000	0.939	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PACSIN3–GBM (DFS)

Open the GBM breakdown →